1. Home
  2. LEE vs RNTX Comparison

LEE vs RNTX Comparison

Compare LEE & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lee Enterprises Incorporated

LEE

Lee Enterprises Incorporated

HOLD

Current Price

$9.52

Market Cap

160.1M

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.28

Market Cap

30.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEE
RNTX
Founded
1890
2001
Country
United States
United States
Employees
N/A
11
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
160.1M
30.0M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
LEE
RNTX
Price
$9.52
$1.28
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
111.9K
84.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$543,955,000.00
N/A
Revenue This Year
$5.48
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.34
$1.02
52 Week High
$11.21
$2.22

Technical Indicators

Market Signals
Indicator
LEE
RNTX
Relative Strength Index (RSI) 64.51 59.42
Support Level $3.87 $1.06
Resistance Level $9.74 $1.57
Average True Range (ATR) 0.83 0.11
MACD -0.08 0.02
Stochastic Oscillator 70.65 73.33

Price Performance

Historical Comparison
LEE
RNTX

About LEE Lee Enterprises Incorporated

Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: